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Non-obese adult onset diabetes with
oral hypoglycemic agent failure: islet
cell autoantibodies or reversible beta
cell refractoriness?
Abstract
Pancreatic ß cell function and insulin sensitivity, analyzed by the
homeostasis model assessment, before and after 24 weeks of insulin
therapy were studied and correlated with the presence of autoantibod-
ies against ß cells (islet cell and anti-glutamic acid decarboxylase
antibodies), in a group of 18 Brazilian lean adult non-insulin-depend-
ent diabetes mellitus (NIDDM) patients with oral hypoglycemic agent
failure (OHAF). Median fasting plasma glucose before and after
insulin treatment was 19.1 and 8.5 mmol/l, respectively (P < 0.001);
median HbA1c was 11.7% before vs 7.2% after insulin treatment (P <
0.001). Forty-four percent of the patients were positive (Ab+) to at
least one autoantibody. Fasting C-peptide levels were lower in Ab+ than
Ab- patients, both before (Ab+: 0.16 ± 0.09 vs Ab-: 0.41 ± 0.35 nmol/l,
P < 0.003) and after insulin treatment (Ab+: 0.22 ± 0.13 vs Ab-: 0.44 ±
0.24 nmol/l, P < 0.03). Improvement of Hß was seen in Ab- (median
before: 7.3 vs after insulin therapy: 33.4%, P = 0.003) but not in Ab+
patients (median before: 6.6 vs after insulin therapy: 20.9%). These
results show that the OHAF observed in the 18 NIDDM patients
studied was due mainly to two major causes: autoantibodies and ß cell
desensitization. Autoantibodies against ß cells could account for 44%
of OHAF, but Ab- patients may still present ß cell function recovery,
mainly after a period of ß cell rest with insulin therapy. However, the
effects of ß cell function recovery on the restoration of the response to
oral hypoglycemic agents need to be determined.
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Introduction
Oral hypoglycemic agent failure (OHAF)
among all patients diagnosed with type 2
diabetes mellitus (T2DM) is heterogeneous
regarding pathogenesis and biological mark-
ers. It is known that about 10 to 30% of
newly diagnosed patients initially classified
as T2DM have little or no glycemic response
to sulfonylurea (primary failure) (1,2). In
addition, after each year of treatment, ap-
proximately 5 to 10% of T2DM patients who
have achieved fair or good metabolic control
lose their responsiveness to sulfonylureas
(secondary failure) (1,2). Recently, the United
Kingdom Prospective Diabetes Study (2)
found a 7.3% annual incidence of secondary
failure to sulfonylureas (chlorpropamide or
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glyburide) in newly diagnosed T2DM.
Two major factors can exert influence on
ß cell function in patients initially classified
as T2DM: the presence of autoantibodies
against ß cells (3,4) and chronic hyperglyce-
mia (desensitization or glucotoxicity) (5).
Glutamic acid decarboxylase antibodies
(GAD65Ab) and islet cell antibodies (ICA)
are useful humoral markers of both type 1
diabetes mellitus (T1DM; 6) and latent au-
toimmune diabetes of the adult (7,8). The
term glucose desensitization refers to a tem-
porary physiological state of ß cell refracto-
riness to glucose stimulation induced by re-
peated or prolonged exposure to high con-
centrations of glucose. It is reversed in a
time-dependent manner after restoration of
normal glucose concentrations and implies
involvement of an intrinsic and reversible
alteration in stimulus-secretion coupling (5).
The term glucose toxicity should be reserved
for nonphysiological and potentially irre-
versible ß cell damage caused by chronic
exposure to supraphysiological glucose
concentrations. The ß cell damage is charac-
terized by defective insulin gene expression
(5). Chronic hyperglycemia may cause ß cell
dysfunction due to oxidative stress activation
of nuclear factor κB, which reduces insulin
mRNA and insulin secretion and induces a
proapoptotic event in ß cells (9). It has also
been well established that glycemic control
with insulin may restore ß cell sensitivity to
glucose in some of the T2DM patients (10).
The aim of the present study was to deter-
mine the effect of 24 weeks of insulin thera-
py on ß cell function and insulin sensitivity
and to correlate it with the presence of ICA
in a group of lean adult apparent T2DM
patients with OHAF.
Patients and Methods
Patients
Eighteen lean apparent T2DM adult pa-
tients (11 males/7 females, median age 45.5
years, median age at diagnosis 41 years,
median time since T2DM diagnosis 30
months and mean ± SD body mass index
(BMI) = 22.1 ± 3.0 kg/m2) with OHAF,
without previous insulin treatment and no
ketoacidosis at diagnosis were studied. Pri-
mary and secondary OHAF were observed
in 39% (7/18) and 61% (11/18) of them,
respectively. Eleven patients had a positive
family history of diabetes mellitus. They
were recruited from the outpatient diabetic
clinic at the Division of Endocrinology of
Hospital São Paulo, UNIFESP, São Paulo,
SP, Brazil. The patients were initially classi-
fied as T2DM according to the guidelines of
the American Diabetes Association (11). The
criteria used for defining an OHAF were a
persistently higher than 11 mmol/l fasting
blood glucose while receiving a maximum
dose of first- or second-generation sulfonyl-
ureas, in the absence of active infectious
disease, and a history of alcoholism or dia-
betes associated with other endocrine dis-
eases. Primary OHAF was considered to be
present when an adequate response to a maxi-
mal dose of oral hypoglycemic agents could
not be achieved within at least 1 month of
treatment (12). Secondary OHAF was de-
fined as the loss of response to oral hypogly-
cemic agents after at least 6 months of good
metabolic control (2).
Design and treatment
The study was conducted over a period
of 24 weeks of diet plus insulin therapy. Oral
hypoglycemic agents were withdrawn after
the first clinical evaluation and blood samples
were collected after a 12-h fast in order to
determine fasting plasma glucose (FPG), fast-
ing C-peptide (FCP), glycosylated hemoglo-
bin (HbA1c), ICA and GAD65Ab values. A
urine sample was also obtained for the deter-
mination of ketonuria. Patients received an
individualized diet (50% carbohydrates, 20%
protein, 30% fat, preferentially mono- and
polyunsaturated) and insulin therapy was
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started with intermediate action (NPH) insu-
lin once or twice a day. The patients were
followed for 24 weeks with medical appoint-
ments every 15 days. The same physicians
performed all evaluations. The biochemical
and hormonal measurements were repeated
after 24 weeks. The Ethics Committee for
Human Research of the University Hospital
approved the protocol and written informed
consent was obtained from all patients.
Assays
FPG was determined by the glucose-oxi-
dase method, with normal values ranging
from 3.8 to 6.4 mmol/l. HbA1c was deter-
mined by affinity chromatography (13), with
normal values ranging from 2.6 to 5.6%.
FCP was determined by radioimmunoassay
(14) using the anti-C peptide K6 antibody
(Novonordisk Laboratory, Gentofte, Den-
mark). The normal values for this assay
ranged from 0.15 to 0.52 nmol/l and the
lowest detection limit was 0.01 nmol/l. Ke-
tonuria was determined by the semiquantita-
tive nitroprusside method. ICA were meas-
ured by the immunoperoxidase method with
protein A-peroxidase (15) using cryostatic
sections of Wistar rat pancreas as substrate.
Two independent observers read the sec-
tions, prepared in duplicate, on a double-
blind basis. GAD65Ab were measured by a
radiobinding assay using [35S]-recombinant
GAD65. This assay had a 6.7% interassay
coefficient of variation. The results are re-
ported as GAD65Ab index and values higher
than one were considered to be positive (16).
Beta cell function and insulin sensitivity were
calculated from pairs of FPG and FCP by the
homeostasis model assessment (HOMA) us-
ing a computer program obtained from Dr.
Jonathan C. Levy, Diabetes Research Labo-
ratories, Radcliff Infirmary, Oxford, UK (17).
Statistical analysis
Statistical analyses were performed us-
ing the SigmaStat software. Data are re-
ported as the mean ± SD or median. The
statistical difference between two variables
was calculated by the Mann-Whitney U-test
or by Kruskal-Wallis one-way analysis of
variance on ranks test. For paired data,
Wilcoxon’s test was used. Spearman’s rank
test (rS) was used to determine the correla-
tion between variables. A P value less than
0.05 was considered to be significant.
Results
There was a positive correlation between
the chronological age at diabetes diagnosis
and the time to develop OHAF (rS = 0.47,
P < 0.05). The patients’ BMI before insulin
therapy was 22.1 ± 3.0 kg/m2 (median: 22.6
kg/m2, range: 14.8-26.7 kg/m2) and did not
change significantly after insulin treatment.
Ketoacidosis was not present in any of
these patients when diabetes was diagnosed
but 55.5% of them had ketonuria at our first
laboratory evaluation. Pre-insulin treatment
FPG and HbA1c were 20.1 ± 6.6 mmol/l
(median: 19.1 mmol/l) and 12.1 ± 2.3% (me-
dian: 11.7%), respectively. After insulin treat-
ment, these values were 9.7 ± 4.5 mmol/l
(median: 8.5 mmol/l) and 7.6 ± 2.2% (me-
dian: 7.2%), respectively (P < 0.001 for FPG
and HbA1c). Before insulin therapy the ba-
sal FCP levels of these patients ranged from
0.07 to 1.34 nmol/l, with a mean of 0.30 ±
0.29 nmol/l and a median of 0.23 nmol/l.
After 24 weeks of insulin treatment, FCP
levels increased to 0.34 ± 0.22 nmol/l, but
this difference was not significant. There
was a correlation between FCP values be-
fore and after insulin treatment (rS = 0.84,
P < 0.0001); FCP before and after insulin
treatment also correlated with time since
diabetes diagnosis (before: rS = 0.67, P <
0.003 and after: rS = 0.74, P < 0.0001) and
with BMI (before: rS = 0.53, P < 0.03 and
after: rS = 0.49, P < 0.05).
In the group of OHAF patients as a whole,
insulin treatment improved ß cell function
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(before insulin: HOMA ß: 6.6%, 1.8-261.7
and after insulin: 31.9%, 5.9-135.4; P =
0.008). Insulin sensitivity also tended to im-
prove (before insulin: HOMA S: 51.9%, 3.9-
440.0 and after insulin: 131.5%, 32.3-1354.0;
P = 0.070).
Forty-four percent of the patients were
positive for at least one of the ICA studied.
ICA were present in 27.8% (5/18) of the
patients and GAD65Ab in 33.3% (5/15).
Autoantibody-positive and -negative patients
were analyzed separately (Table 1). ICA-
and/or GAD65Ab-positive patients were
younger than autoantibody-negative patients
(38.5 ± 15.2 years, median = 30.5 years vs
49.7 ± 12.4 years, median = 50 years; P =
0.07). The time since diabetes diagnosis was
shorter for autoantibody-positive patients
(16.2 ± 29.9 months, median = 2.5 months vs
54.6 ± 40.2 months, median = 48 months;
P < 0.002). The prevalence of primary fail-
ure was higher in autoantibody-positive
(75%) than in autoantibody-negative (10%)
patients (P < 0.05). In contrast, secondary
failure was more frequent in autoantibody-
negative (90%) than in autoantibody-posi-
tive (25%) patients (P < 0.05). No significant
differences were found concerning the pres-
ence of ketonuria, FPG and HbA1c between
patients with or without autoantibodies. FCP
levels were lower in autoantibody-positive
than in autoantibody-negative patients both
before (0.16 ± 0.09 vs 0.41 ± 0.35 nmol/l; P
< 0.003) and after insulin treatment (0.22 ±
0.13 vs 0.44 ± 0.24 nmol/l; P < 0.03) (Figure
1). No difference in FCP values was ob-
Table 1. Clinical and laboratory characteristics of diabetic patients with oral hypoglycemic agent failure
according to positivity for ICA and/or GAD65Ab.
Ab+ Ab-
N 8 (44.4%) 10 (55.6%)
Age (years) 38.5 ± 15.2 49.7 ± 12.4
Sex (male/female) 4/4 7/3
Time since diagnosis (months) 16.2 ± 29.9 54.6 ± 40.2*
Primary failure (%) 75 10*
Secondary failure (%) 25 90*
BMI (kg/m2) 20.9 ±2.9 23.0 ± 2.9
Ketonuria (positive/negative) 5/3 (62.5% pos.) 5/5 (50% pos.)
FPG (mmol/l) before insulin Tx 17.1 ± 5.5 22.5 ± 6.6
FPG (mmo/l) after insulin Tx 9.3 ± 4.4** 10.1 ± 4.7**
HbA1c (%) before insulin Tx 12.4 ± 1.9 12.0 ± 2.7
HbA1c (%) after insulin Tx 7.8 ± 2.6** 7.3 ± 2.0**
FCP (nmol/l) before insulin Tx 0.16 ± 0.09 0.41 ± 0.35*
FCP (nmol/l) after insulin Tx 0.22 ± 0.13 0.44 ± 0.24*
ICA+ 5/8 (62.5%) 0
GAD65Ab+ 5/8 (62.5%) 0
ICA and GAD65Ab+ 2/8 (25%) 0
ICA or GAD65Ab+ 8/8 (100%) 0
HOMA ß (%, median and range) before insulin Tx 6.6 (1.8-262.7) 7.3 (2.2-29.2)**
HOMA ß (%, median and range) after insulin Tx 20.9 (5.9-79.2) 33.4 (8.0-135.4)**
HOMA S (%, median and range) before insulin Tx 115.5 (3.9-440.0) 50.0 (17.9-168.0)
HOMA S (%, median and range) after insulin Tx 149.7 (97.7-1354.0) 92.1 (32.3-475.6)*
Ab+ = autoantibody-positive patients; Ab- = autoantibody-negative patients; BMI = body mass index; FCP =
fasting C-peptide; FPG = fasting plasma glucose; GAD65Ab+ = glutamic acid decarboxylase antibodies;
HbA1c = glycosylated hemoglobin; HOMA ß and HOMA S = ß cell function and insulin sensitivity, respec-
tively, as analyzed by the homeostasis model assessment; ICA = islet cell antibodies; Tx = treatment.
Data are reported as means ± SD.
*P < 0.05, Ab- compared to Ab+ (Mann-Whitney U-test); **P < 0.05, before versus after insulin treatment
(Wilcoxon’s test).
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dian age was 41 years.
Our data indicate that a higher age at
diabetes diagnosis was associated with a
longer insulin-independent phase. Differ-
ently, Humphrey et al. (21) found that age at
diagnosis did not correlate with the duration
of the non-insulin-dependent phase. How-
ever, in the UK Prospective Diabetes Study
(2), younger age was one of the factors re-
lated to higher failure of oral hypoglycemic
agents or to shorter insulin-independent
phase.
Ketonuria was present in 55.5% of our
patients at first laboratory evaluation, in
agreement with data indicating that ketosis
is often associated with insulin deficiency
(22). However, although ketonuria may in-
dicate insufficient insulin action, it is not
equal to insulin dependence. Insufficient in-
sulin action may be due to either absolute
insulin deficiency or severe insulin resis-
tance (23). According to Hother-Nielsen et
served before and after insulin treatment
within the two groups of patients (autoanti-
body-positive and autoantibody-negative).
FCP levels, before and after insulin treat-
ment, were correlated positively in both sub-
groups (rS = 0.88, P < 0.0001).
Beta cell function (HOMA ß) improve-
ment by insulin treatment was observed in
autoantibody-negative patients (before insu-
lin: median, 7.3%; range, 2.2-29.2% vs after
insulin: median, 33.4%; range, 8.0-135.4%;
P = 0.0034), but not in autoantibody-positive
patients (before insulin: median, 6.6%; range,
1.8-262.7% vs after insulin: median, 20.9%;
range, 5.9-79.2%) (Figure 2; Table 1). There
was also a correlation between ß cell func-
tion, before and after insulin treatment, in
autoantibody-negative patients (rS = 0.84,
P = 0.005), but not in autoantibody-positive
patients.
When insulin sensitivity (HOMA S) was
compared between autoantibody-positive and
-negative patients after insulin treatment, it
was higher in the former group (median,
149.7; range, 97.7-1354.0 vs median, 92.1;
range, 32.3-475.6; P = 0.026, respectively).
These results are shown in Table 1.
Discussion
The identification of diabetes type is
sometimes difficult in non-obese adults aged
25 to 50 years (18,19). A subset of these
patients may develop OHAF more rapidly.
In these OHAF patients initially classified as
T2DM, many different etiopathogenic
mechanisms can be involved. One third of
these patients have a late-onset and slowly
evolving autoimmunity against ß cells (la-
tent autoimmune diabetes of the adult) (8)
and others may have a dysfunction of ß cells
and/or a decrease in insulin sensitivity in-
duced by chronic hyperglycemia (5,20).
This was a pilot study carried out to
determine the presence of these factors in a
group of lean diabetic patients with both
primary and secondary OHAF, whose me-
Figure 2. Comparison of homeo-
stasis model assessment ß
(HOMA ß) between autoanti-
body-positive  (Ab+) and autoan-
tibody-negative (Ab-) diabetic
patients with oral hypoglycemic
agent failure, before and after
insulin treatment (Tx). The sta-
tistical tests used were Mann-
Whitney rank-sum test and Wil-
coxon signed rank test. NS =
nonsignificant.
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al. (23), several non-insulin-requiring pa-
tients, with stimulated C-peptide values far
above the discriminatory C-peptide level,
can have ketonuria of considerable magni-
tude. The results of another study (24) also
indicated a wide heterogeneity of clinical
subtypes among patients who develop ketosis.
Glycemic control was poor at entry (me-
dian HbA1c: 11.7%) and improved signifi-
cantly after 24 weeks of insulin therapy (me-
dian HbA1c: 7.2%), suggesting that the high
glucose concentrations at entry could be re-
sponsible for ß cell desensitization. In an-
other similar study, this level of metabolic
control achieved after insulin treatment
seemed to restore sensitivity to sulfonylurea
by enhancing ß cell secretory activity in non-
obese T2DM patients (25).
Serum C-peptide has been considered a
valuable method of monitoring pancreatic ß
cell function in diabetic patients, whether or
not they are receiving insulin treatment (26),
and therefore we chose this parameter for
the present study. The ß cell function of our
patients was heterogeneous, as suggested by
the wide amplitude of variation of FCP both
before and after insulin treatment. FCP lev-
els before and after insulin treatment showed
a good correlation.
In a previous study from our laboratory,
we showed that classic T1DM and T2DM
patients had a mean FCP value of 0.15 ± 0.15
and 0.69 ± 0.29 nmol/l, respectively, within
the first 6 months of clinical diagnosis (27).
FCP values for the total group of OHAF
patients studied were intermediate between
those of T1DM and T2DM. However, 44%
of our OHAF patients had FCP below 0.20
nmol/l and they could be classified as insulin
deficient according to the endocrine criteria
used to separate T1DM from T2DM (28,29).
These data are similar to those obtained in
another study that showed that about one
third of non-insulin-dependent diabetic pa-
tients with secondary OHAF are permanently
insulin deficient (30).
Humphrey et al. (21), however, observed
that up to 40% of diabetic adults have equivo-
cal C-peptide results at any post-diagnosis
stage and that C-peptide measurement alone
may be of little utility in distinguishing be-
tween T1DM and T2DM. Glucagon-stimu-
lated C-peptide levels have a poor negative
predictive value for secondary OHAF in
T2DM; indeed, less than 30% of the subjects
with very low levels require insulin (31). So
far, the decision to treat with insulin is usu-
ally made on clinical grounds and the cut-off
value for hyperglycemia is not consensual
(32).
HOMA (33), a structural computer mo-
del of the glucose-insulin feedback system,
performs well in comparison with several
tests of insulin sensitivity and ß cell func-
tion, including the hyperglycemic clamp, the
oral glucose tolerance test and the intrave-
nous glucose tolerance test. However, intra-
subject variability of 30% in normal and
diabetic subjects limits the interpretation of
individual data. According to a recent study
by Taverna et al. (32), HOMA ß is a better
predictor of the insulin-requiring stage in
long-standing T2DM patients with second-
ary OHAF than clinical indices, such as long
duration of diabetes and/or elevated glyce-
mic levels.
In the present study, we observed that
both ß cell function and insulin sensitivity
improved after the attenuation of the
glucotoxic effect. It has been demonstrated
that hyperglycemia can be improved by short-
term insulin therapy in T2DM patients (34).
On the other hand, a recent study showed
that the deficiency in glucose metabolism
could rapidly return if insulin therapy is
discontinued (35). Therefore, other mechan-
isms might be involved in the OHAF pro-
cess.
One of these mechanisms could be slowly
progressive autoimmune modifications. Con-
cerning our patients, the positivity of
GAD65Ab (33.3%) and ICA (27.8%) was
higher than the percentage detected by other
investigators in patients primarily classified
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as T2DM (36,37). An explanation for this
fact may be related to patient age, the criteria
used to define primary and secondary OHAF
and also to the fact that these were not obese
patients. Furthermore, up to 2.4% of healthy
subjects are positive for GAD65Ab (38).
Groop et al. (37) detected a 14% fre-
quency of ICA-positive patients aged 35-75
years at diagnosis. However, these patients
were older than those evaluated in our study.
Concerning GAD65Ab, Niskansen et al. (38)
found 9% positivity, but obese patients with
a higher mean age were also included. In a
study of young adult diabetic patients,
Hagopian et al. (39) detected 21% positivity
for GAD65Ab. Tuomi et al. (7), studying
non-obese adult onset diabetic patients, found
that one third of them probably corresponded
to latent autoimmune diabetes of the adult,
since 33% of them presented low C-peptide
levels and 76% of them were GAD65Ab
positive. Zimmet et al. (8) reported similar
results for non-obese adult diabetic patients
using insulin. Therefore, the percentage
(44%) of autoantibody positivity in our group
is intermediate between that found in classic
T2DM and in latent autoimmune diabetes of
the adult patients. This may suggest that
autoimmunity does not totally explain the
OHAF of our patients.
We cannot also totally exclude the possi-
bility that the presence of autoantibodies
against pancreatic ß cells in our patients
represents an epiphenomenon. The autoanti-
bodies are serological markers of T-cell-
mediated ß cell destruction (38). They can
also be released in response to the metabolic
injury rather than being a primary event. It is
known that high glucose concentrations can
strongly stimulate the synthesis of GAD65,
possibly exacerbating an autoimmune pro-
cess (40).
When the clinical and metabolic charac-
teristics of OHAF patients with and without
autoantibodies were compared, it was ob-
served that they did not differ in relation to
sex, BMI, FPG or HbA1c levels, either be-
fore or after insulin treatment. However,
patients positive for autoantibodies tended
to be younger than those negative for au-
toantibodies and early or primary sulfonyl-
urea failure occurred in the majority of them
(75%), similar to data published by others
(37).
Beta cell function and insulin sensitivity
before and after a period of insulin therapy
were also compared by HOMA in the two
groups of OHAF diabetic patients (autoanti-
body-positive and autoantibody-negative
subjects). It is important to emphasize that
BMI was unchanged in the two groups, both
before and after insulin therapy, providing
more reasonable conditions for HOMA com-
parison. Beta cell function improved in au-
toantibody-negative patients after 24 weeks
of insulin therapy, but not in autoantibody-
positive patients. This suggests that there is a
point of no return of ß cell function, which
may be related to an autoimmune insulitis
process in these autoantibody-positive OHAF
diabetic patients. The improvement in ß cell
function in the autoantibody-negative group
could be due to a decrease in the grade of
desensitization of ß cells to glucose. On the
other hand, the insulin sensitivity after insu-
lin treatment was better in the autoantibody-
positive group than in the autoantibody-nega-
tive group. Interestingly, the ß cell function
of autoantibody-positive OHAF patients af-
ter insulin treatment (20.9%) was similar to
that of the patients of the UK Prospective
Diabetes Study (26.2%) who progressed to
insulin dependency after 6 years of diabetes
(2).
The results of the present study are con-
sistent with the pathogenetic heterogeneity
of OHAF in lean adult non-insulin-depend-
ent diabetic patients. Thus, autoimmunity
against, or desensitization of, pancreatic ß
cells can be found in a group of non-obese
adult diabetics with OHAF.
Sometimes the phenotype of adult au-
toantibody-positive patients resembles that
of autoantibody-negative patients. The pres-
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ence of autoantibodies against ß cells in-
creases the likelihood of ß cell function dete-
rioration, even after sustained improvement
of glycemic control by means of insulin treat-
ment.
Primary and secondary OHAF appear to
separate autoantibody-positive and -nega-
tive patients quite well. In addition, our data
suggest that in autoantibody-negative pa-
tients with OHAF ß cell function may im-
prove after a period of insulin therapy. How-
ever, the effects of this recovery on the resto-
ration of sensitivity to oral hypoglycemic
agents need to be studied further.
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